Study FAQs

What’s the difference between the ADNI 1, ADNI GO, and ADNI 2 studies?

Although the three studies all aim to advance AD research, you will find differences in participant pools, and adjustments to data collection protocols over time as a result of scientific findings and changing technologies. These differences are outlined in the Study Objectives, and the Data & Samples sections for each core. For instance, DTI data is available from some ADNI GO and ADNI 2 subjects, as this is fairly new technology. ADNI manuals, procedures are protocols from each study are available on the ADNI Documents: Procedures, Protocols, and Manuals webpage for download.

How can I acknowledge/cite the ADNI data/protocols?

Acknowledgement requirements are detailed in the Data Sharing and Publications Policy. This and other relevant documents can be found on the webpage, “How to Apply for Data“.

Where can I sign up for a Clinical Test?

Please visit the Alzheimer’s Disease Education and Referral (ADEAR) Center Website for a listing of open clinical studies. You can sign up at one of our acquisition site locations, in the US or Canada. Browse our map on the Study Site page.

What is a Biomarker?

A biomarker, or biological marker, is a substance, measurement or indicator of a biological state. Biomarkers may exist before clinical symptoms arise. ADNI uses various biomarkers to help predict the onslaught of Alzheimer’s disease. Read more about biomarkers on the study Background & Rationale webpage.

I’d like to interview ADNI for the Press. Who can I contact?

Mike Weiner is the principle investigator of ADNI. Read his bio and get his contact information from the Administrative Core webpage.